Roche provides innovative clinical diagnostic, dPCR, next-gen sequencing, and digital solutions to empower your lab. We are dedicated to creating diagnostic tools and developing techniques that are tailored to individual genetic and disease profiles, meeting the demands of research and clinical practice to deliver on the promise of personalized healthcare.
Introducing the next-generation of Molecular testing automation regardless of size, testing volume or mix. Improve productivity and reduce error, maximize the value of your lab space, scale efficiently as demands change, and ensure consistency across testing with standardized assays.
An automated approach to syndromic infectious disease testing for multiple disease states, including respiratory and bloodstream infections. The cobas® eplex system sample-to-answer capabilities integrate the whole process from order-to-report to better realize the patient and laboratory benefits of rapid, multiplex molecular diagnostics.
Light the way from research to clinical diagnostics with Roche's new IVD and RUO workflow capability real-time PCR system. Built upon proven technology, the LightCycler® PRO allows the ability to amplify confidence in your results, adapt quickly to your evolving testing needs, and simplify your workflow.
A digital PCR system for DNA and RNA with a 6-color capability for flexible, multiplexed biomarker detection. With advances in sensitivity, precision, flexibility, and integration, the Digital LightCycler® System is a powerful digital PCR system that aims to help laboratories push the boundaries of clinical research forward.
Bring the power of Foundation Medicine® and Roche into your lab. The AVENIO Tumor Tissue CGP Kit V2 is an in-house next-generation sequencing (NGS) research assay that provides comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue-derived DNA samples. With a 335-gene panel aligned with the FoundationOne®CDx panel design and bioinformatics using the FoundationOne®Analysis Platform, the kit leverages the proven technology of Foundation Medicine and expertise of Roche to help your lab obtain reliable genomic insights.
Designed to empower your laboratory with a complete end-to-end 5-day workflow from tissue DNA extraction to results generation with ready-to-use, non-toxic reagents, robust bioinformatics, secondary analysis, and true walk-away automation with the AVENIO Edge System.
Simplify NGS library prep with the AVENIO Edge System, a fully automated platform for end-to-end library prep, target enrichment, quantification, pooling, and normalization. Designed for easy setup — even for users with no NGS or automation experience - with ready-to-load barcoded reagent cartridges and intuitive software.
navify® Mutation Profiler ‡ is a Next Generation Sequencing (NGS) reporting solution that can help labs & researchers confidently, clearly and efficiently interpret the significance of mutations. navify® Mutation Profiler increases lab efficiency and enables scalability by helping reduce curation time and by automating report generation.
navify® Analytics provides lab directors/managers with an easier way to track, review, and identify operational trends and challenges. This increased visibility guides the decision-making process toward optimizing operations, customer delivery, and overall lab performance in a targeted and efficient manner. navify® Analytics converts operational data directly from the instruments, enabling better utilization of resources.
navify® Lab Operations automates the three main areas of the lab operations, pre-analytics, analytics and post analytics — but also extends beyond the lab to manage ordering, sample collection, validation and reporting. It enables a paperless workflow, and is structured around work areas that focus on the tasks in hand. The advanced workflow engine manages the sample processing and auto-validation enables efficient result management.
* The AVENIO Tumor Tissue CGP Kit portfolio is for Research Use Only. Not for use in diagnostic procedures.
† Product in development. Not available in the U.S.
** AVENIO Edge reagents and workflows are for Research Use Only. They are not intended for diagnostic applications.
‡ navify® Mutation Profiler is for Research Use Only in the US. Not for use in diagnostic procedures.
FOUNDATIONONE is a trademark of Foundation Medicine, Inc.
Vancouver Convention Centre | Location: 205 - 207, Level 2
Molecular diagnostic developers face both internal and external pressures to reduce costs and improve assay performance. For example, the reverse transcription step in an RT-PCR assay drastically increases complexity encountered in molecular diagnostics. Using fast, inhibitor tolerant, and lyo-compatible reverse transcriptases can help reduce the burden on developers by enabling short overall turnaround times, streamlining or eliminating purification, and simplifying shipping and storage. Selecting the appropriate components to address the challenges in your assay can be a daunting task. At Roche CustomBiotech, we are here to assist you in finding solutions and overcoming these obstacles. Explore our wide range of reagents designed for the unique requirements of centralized and point-of-care diagnostic assay development.
Precision oncology is rapidly evolving, often driving clinical trials through a biomarker-centric approach and identifying new treatment targets. The significance of genomic signatures, such as Homologous Recombination Deficiency (HRD), has grown considerably, necessitating ongoing advancements in assay and bioinformatics development. Roche and Foundation Medicine have introduced the updated AVENIO Tumor Tissue CGP Kit V2 * † (Research Use Only), featuring improved workflows and bioinformatics, shorter wet-lab procedures, reduced sequencing costs, the addition of emerging oncology genes, enhanced variant calling algorithms, and a new pan-cancer HRD signature developed by Foundation Medicine. The updated AVENIO Tumor Tissue CGP Kit V2 maintains robust performance while enabling laboratories to expand their sequencing research capabilities.
navify® Mutation Profiler ‡ (nMP) supports precision oncology research by converting complex NGS data into relevant insights. With up-to-date regional guidelines, approvals, and clinical trials, it offers a secure, cloud-based solution for variant interpretation and delivers comprehensive customizable or standardized reports. navify® MP is powered by expert-curated content for 19 solid tumor types and 48 hematological malignancies, encompassing >33,000 curated variants, >12,250 biomarker profiles, and >1,000,000 biomarker/disease associations. In conjunction with AVENIO Tumor Tissue CGP kits*, navify® MP provides functionality to interpret and report the new pan-tumor HRD signature (HRDsig) score. Leveraging a powerful algorithm trained on Foundation Medicine’s vast pan-tumor genomic database with over 100 unique genomic features, HRDsig distinguishes itself from all other HRD scores on the market.
The new AVENIO Tumor Tissue CGP Automated Kit * †, developed by Roche and Foundation Medicine, is a Research Use Only product designed for comprehensive genomic profiling of solid tumor specimens. It analyzes 335 genes, 4 alteration classes, and 4 genomic signatures. Featuring a panel aligned with FoundationOne® CDx panel design and robust bioinformatics from the FoundationOne® Analysis Platform, it includes a new pan-tumor HRD signature developed by Foundation Medicine. The kit offers fully automated library preparation and target enrichment with 24 hours of walk-away time via the AVENIO Edge ¶, and approximately 3.5 hours of hands-on time from DNA extraction to results. The AVENIO Tumor Tissue CGP Automated Kit is designed to radically simplify sequencing workflows through automation.
This presentation offers an in-depth examination of the early stage-NSCLC biomarker landscape, focusing particularly on clinical data pertaining to PD-L1, EGFR, and ALK, given the increasing importance of immunotherapies and targeted treatments in the adjuvant setting. Despite the evident advantages of comprehensive biomarker testing, obstacles persist in ensuring broad access to testing platforms and accurately interpreting results. Using EGFR and ALK biomarker testing as a case study, we will explore its significance, available testing methodologies, and appropriate timing for its application. Furthermore, we will address challenges associated with EGFR and ALK testing, strategies for its integration in different practice settings, and clinical data demonstrating the importance of EGFR and ALK-targeted therapy in the adjuvant setting.
Come learn how a clinical laboratory is leveraging the precision, sensitivity, and flexibility of Roche’s Digital LightCycler® dPCR System. The System‘s six detection channels and three consumable configurations (20k, 28k, or 100k nanowell partitions) enable diverse applications with clinical utility (e.g., rare mutation detection, copy number variation, gene expression analysis, methylation assessment) across a broad range of sample volumes. Hear the lab explain how the sensitive performance of the Digital LightCycler® System has become a powerful addition to their laboratory.
Congenital Cytomegalovirus (cCMV) screening presents unique challenges for laboratories, particularly due to the relatively low incidence of the condition. This workshop will explore the complexities of newborn cCMV screening using nucleic acid amplification tests (NAAT). Participants will learn about quality management strategies to reduce false positives, including repeat testing. The workshop will also discuss the future of universal cCMV screening in the US, emphasizing the need for higher-throughput automated assays and cost-effective solutions. Join us to gain insights into optimizing cCMV screening protocols and overcoming the hurdles in making universal screening a reality.
* The AVENIO Tumor Tissue CGP Kit portfolio is for Research Use Only. Not for use in diagnostic procedures.
† Product in development. Not available in the U.S.
‡ navify® Mutation Profiler is for Research Use Only in the US. Not for use in diagnostic procedures.
§ For further processing only or For use in quality control/manufacturing process only.
¶ AVENIO Edge reagents and workflows are for Research Use Only. They are not intended for diagnostic applications.
FOUNDATIONONE is a trademark of Foundation Medicine, Inc.
Visit our booth to explore the transformative power that lies within our partnerships and how our products can empower your institution from research to diagnostics that provide accurate results clinicians need to help improve patient care.
